Semnurpharma - Getting back to normal

Getting back to normal

About
Partners
Chronic Back Pain
Science
Investors
Join Our Team
Contact Us

Analyst Coverage

Contact Investor Relations

Semnur is covered by the following analysts:

Firm	Analyst Name
H.C. Wainright & Co.	Ram Selvaraju
Rodman & Renshaw	Elemer Pieros
Zacks	Brad Sorensen
B. Riley	Mayank Mamtani

Overview
Partners
Our Culture
Product
Publications
Join Our Team
Presentation
Contact Us

Connect, follow and have a conversation with us

960 San Antonio Road, Palo Alto, CA, 94303
(650) 516-4310
info@semnurpharma.com

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Announces on November 6th, 2024 the Filing of a Registration Statement on Form S-4 by Denali Capital Acquisition Corp. with the Securities and Exchange Commission Relating to the Previously Announced Proposed Business Combination Between Semnur and Denali.

Check Our Press Release

… heavy objects, or some other non-specific back injury.

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

Reference:
@srinipillay 2016:https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

The overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million across all Medicare and private coverage patients, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered, according to a proprietary study by Syneos Health. *

References:
* Syneos Health

Getting back to normal

Analyst Coverage